Applying Structured Glucose Monitoring and Escalation Thresholds in HR+/HER2-Negative Advanced Breast Cancer

In this segment, Dr. Neil Iyengar moderates a multidisciplinary discussion on how structured fasting-glucose monitoring approaches are applied in real-world practice for patients with HR+/HER2-negative advanced breast cancer initiating AKT pathway therapy. The panel reflects on expert consensus guidance and prescribing information that outline recommended monitoring cadences and thresholds for intervention, including when clinicians may consider initiating antihyperglycemic therapy or involving endocrinology. Panelists discuss how these frameworks are adapted to individual patient risk profiles, balancing proactive monitoring with practical considerations such as patient burden and access to follow-up care. The conversation emphasizes the importance of early trend recognition, clear communication with patients, and coordinated decision-making across the care team. This segment highlights how structured monitoring strategies support timely intervention, reduce the risk of severe metabolic complications, and help maintain treatment continuity in routine clinical practice.